Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Biological drugs have improved the lives of many people with severe asthma. However, a new study from Karolinska Institutet ...

Patients with asthma and allergic bronchopulmonary aspergillosis experienced improvements with dupilumab, according to data presented at the American Thoracic Society International Conference.Quality ...

Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively ...

NASHVILLE, Tenn. -- Treatment with the biologic dupilumab (Dupixent) was associated with sustained reductions in oral corticosteroid (OCS) use in asthma patients who required both low and high ...

Dupilumab shows long-term efficacy across yearly seasons in patients with type 2 inflammatory asthma.

In a phase 4 trial, dupilumab effectively reduces airway inflammation and mucus plugging, improving lung function and asthma control in patients with moderate to severe type 2 asthma.

Dupilumab improved nasal polyp outcomes and asthma symptoms more than omalizumab in patients with CRSwNP and asthma, according to the head-to-head EVEREST phase 4 trial.

Dupilumab use in asthma linked to higher lymphoma risk, especially T/NK cell types, though overall mortality was lower, new ...

The study tests Dupilumab, a subcutaneous injection, against a placebo. Dupilumab is designed to treat asthma by targeting specific pathways involved in the inflammatory process.

While biological drugs or biologics have improved the lives of many people with severe asthma, a new study shows that some immune cells with high inflammatory potential are not completely eradicated ...